Compare Microchip Technology Inc. (MCHP) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs Smith & Nephew plc — how do they compare? Microchip Technology Inc. trades at $82.61 (market cap $43.72B), while Smith & Nephew plc trades at $30.12 (market cap $12.64B). The key difference: Microchip Technology Inc. is far larger — about 3.5× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.57%). Which is the better fit depends on your goals.
| MCHP | SNN | |
|---|---|---|
Market Cap | $43.72B | $12.64B |
Sector | Technology | Health |
52-Week High | $102.97 | $38.70 |
52-Week Low | $49.02 | $28.73 |
Enterprise Value | $49.01B | $15.41B |
Dividend Yield | 2.26% | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHP trades at $80.64, down 0.4% on the day, with technical indicators signaling a bearish trend. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 expected at $0.70 EPS. Revenue declined to $4.40B in 2025, resulting in a net loss, but margins are projected to recover in 2026. Positive sentiment is driven by AI and aerospace demand, with 68% of analysts rating it a Buy.
Outlook is mixed: strong analyst consensus targets $113.33, but high P/E of 368 and recent net loss pose valuation risks. Key opportunities include AI data center growth and inventory recovery, while supply chain constraints and semiconductor cycle volatility remain headwinds. The stock offers upside if earnings rebound as forecasted.
Smith & Nephew (SNN) trades at $30.43, down 0.54% on the day, with mixed technical signals showing a neutral overall stance. The company demonstrates improving fundamentals with 2024 revenue of $5.81 billion and net income of $412 million, representing a 7.09% margin. Recent product launches including the LYNX COBLATION Wand and CORI XT robotics platform highlight ongoing innovation. Cash flow trends show strong operational performance with $987 million from operations in 2024.
SNN presents a balanced investment case with improving profitability and product innovation offset by recent earnings misses. The stock trades at reasonable valuations (P/E 21.36, P/S 2.17) with analyst consensus leaning Hold (68%). Key risks include execution challenges and competitive pressures, while catalysts include robotics expansion and wound care leadership. The $500 million buyback program supports shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
